American Research & Management Co. lifted its stake in Pfizer Inc. (NYSE:PFE) by 52.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,904 shares of the biopharmaceutical company’s stock after purchasing an additional 15,761 shares during the period. American Research & Management Co.’s holdings in Pfizer were worth $1,665,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PFE. Amundi Pioneer Asset Management Inc. increased its holdings in shares of Pfizer by 81.3% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 19,093,990 shares of the biopharmaceutical company’s stock valued at $691,583,000 after purchasing an additional 8,563,358 shares in the last quarter. BlackRock Inc. grew its holdings in Pfizer by 1.5% during the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock worth $16,308,754,000 after acquiring an additional 6,785,335 shares during the period. Dimensional Fund Advisors LP grew its holdings in Pfizer by 11.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock worth $1,674,223,000 after acquiring an additional 4,998,981 shares during the period. Jensen Investment Management Inc. acquired a new stake in Pfizer during the 2nd quarter worth $110,291,000. Finally, Robeco Institutional Asset Management B.V. grew its holdings in Pfizer by 75.3% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 7,038,854 shares of the biopharmaceutical company’s stock worth $249,807,000 after acquiring an additional 3,024,270 shares during the period. 68.91% of the stock is owned by institutional investors and hedge funds.

A number of research firms have commented on PFE. Morgan Stanley set a $45.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Thursday, September 13th. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Thursday, September 13th. JPMorgan Chase & Co. set a $42.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, September 10th. BMO Capital Markets lifted their target price on shares of Pfizer to $47.00 and gave the stock an “outperform” rating in a report on Friday, September 7th. Finally, Credit Suisse Group set a $40.00 target price on shares of Pfizer and gave the stock a “hold” rating in a report on Thursday, September 6th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $41.89.

In other news, CEO Ian C. Read sold 486,753 shares of Pfizer stock in a transaction on Monday, July 16th. The shares were sold at an average price of $37.36, for a total transaction of $18,185,092.08. Following the transaction, the chief executive officer now directly owns 1,145,693 shares of the company’s stock, valued at $42,803,090.48. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Frank A. Damelio sold 150,484 shares of Pfizer stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $40.00, for a total transaction of $6,019,360.00. Following the transaction, the insider now directly owns 337,391 shares in the company, valued at $13,495,640. The disclosure for this sale can be found here. Over the last three months, insiders have sold 761,230 shares of company stock worth $29,054,690. Insiders own 0.06% of the company’s stock.

Shares of NYSE PFE opened at $44.06 on Monday. The firm has a market cap of $262.28 billion, a PE ratio of 16.63, a PEG ratio of 2.23 and a beta of 0.96. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $44.19. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. The company had revenue of $13.47 billion for the quarter, compared to analysts’ expectations of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the firm posted $0.67 earnings per share. equities analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 4th. Stockholders of record on Friday, August 3rd were given a dividend of $0.34 per share. The ex-dividend date was Thursday, August 2nd. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.09%. Pfizer’s dividend payout ratio is 51.32%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Story: What is a Fiduciary?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.